An Advanced Computational Evaluation for the Most Biologically Active Enantiomers of Chiral Anti-Cancer Agents

(E-pub Ahead of Print)

Author(s): Mohd. Suhail*, Imran Ali

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Cancer is a very dangerous disease, whose treatment can be improved by removing the factors that cause side effects, if the drugs prescribed for cancer, are chiral in nature.

Objectives: A computational evaluation for the most biologically active enantiomeric form of chiral drugs attacking on DNA of the cell, was done for the first time, and compared with the experimental work done by others previously.

Methods: All the enantiomeric structures of the drugs taken in the present study, were obtained using Marvin sketch, and the structure of DNA to be docked with enantiomers, was obtained from the protein data bank. After that, all the enantiomers of the chiral drugs were docked with DNA one by one for the evaluation of the most biologically active enantiomeric form.

Results: The docking study showed that the different enantiomers interacted with DNA differently because of having different arrangements of atoms/groups. The binding affinity of one of the two enantiomeric forms was higher than that of another.

Conclusion: R-methotrexate for breast cancer; R-mitotane for adrenocortical cancer; R-duvelisib for blood cancer, and S-irinotecan for colon cancer, would be a suitable drug with less toxicity as well as other side effects.

Keywords: Cancer, chiral drugs, biologically active enantiomer, computational study, DNA.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1871520621999201230233811
Price: $95

Article Metrics

PDF: 450